Vaxart (Vaxart) FCF Margin % : -202.52% (As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Vaxart FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vaxart's Free Cash Flow for the three months ended in Dec. 2023 was $-13.42 Mil. Vaxart's Revenue for the three months ended in Dec. 2023 was $6.63 Mil. Therefore, Vaxart's FCF Margin % for the quarter that ended in Dec. 2023 was -202.52%.

As of today, Vaxart's current FCF Yield % is -59.80%.

The historical rank and industry rank for Vaxart's FCF Margin % or its related term are showing as below:

VXRT' s FCF Margin % Range Over the Past 10 Years
Min: -97551.4 Med: -351.94 Max: -4.95
Current: -794.42

During the past 13 years, the highest FCF Margin % of Vaxart was -4.95%. The lowest was -97551.40%. And the median was -351.94%.

VXRT's FCF Margin % is ranked worse than
72.97% of 1036 companies
in the Biotechnology industry
Industry Median: -148.935 vs VXRT: -794.42

Vaxart FCF Margin % Historical Data

The historical data trend for Vaxart's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart FCF Margin % Chart

Vaxart Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-141.35

-617.23

-7,285.76

-97,551.40

-980.13

Vaxart Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-127,340.91	-3,807.26	-1,319.96	-3,426.68	-202.52

Competitive Comparison of Vaxart's FCF Margin %

For the Biotechnology subindustry, Vaxart's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxart's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Vaxart's FCF Margin % falls into.

Vaxart FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Vaxart's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-72.324	/	7.379
	=	-980.13 %

Vaxart's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-13.417	/	6.625
	=	-202.52 %

Vaxart FCF Margin % Related Terms

Thank you for viewing the detailed overview of Vaxart's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxart (Vaxart) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NB11:Germany NB11:Germany

Address

170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Executives

W. Mark Watson	director	324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Phillip E Lee	officer: Chief Financial Officer	C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Elaine J Heron	director	6 STONEGATE RD, PONTOLA VALLEY CA 94028
Fuad Ahmad	officer: Interim CFO	461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Edward B Berg	officer: SVP, General Counsel	C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Robert A. Yedid	director	C/O LIFESCI ADVISORS, 250 WEST 55TH STREET, SUITE 3401, NEW YORK NY 10019
Margaret Echerd	officer: VP, Corporate Controller, PAO	3585 MONROE STREET, SANTA CLARA CA 95051
James F. Cummings	officer: Chief Medical Officer	1312 BEACHVIEW ROAD, ANNAPOLIS MD 21403
Julie M Cherrington	director	9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Sean Tucker	officer: Chief Scientific Officer	385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
Wouter Latour	director, officer: President and Chief Executive	385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Todd C Davis	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037